Enzinger P C, Ilson D H
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, USA.
Oncology (Williston Park). 2000 Dec;14(12 Suppl 14):26-30.
Irinotecan (Camptosar) has shown activity in several solid tumor malignancies, including gastric and pancreatic cancer. In vitro studies suggest antitumor activity in esophageal cancer cell lines. Sequence-dependent synergy has been demonstrated in vitro between irinotecan and cisplatin. A phase I trial conducted at Memorial Sloan-Kettering Cancer Center (MSKCC) has demonstrated the safety and tolerability of cisplatin plus irinotecan. A phase II study of this combination in patients with previously untreated, advanced esophageal cancer, also at MSKCC, has demonstrated promising results. Current trials at MSKCC are attempting to combine this regimen with either paclitaxel (Taxol), fluorouracil (5-FU), or radiation therapy.
伊立替康（开普拓）已在多种实体瘤恶性肿瘤中显示出活性，包括胃癌和胰腺癌。体外研究表明其对食管癌细胞系具有抗肿瘤活性。伊立替康和顺铂在体外已证明存在序列依赖性协同作用。纪念斯隆凯特琳癌症中心（MSKCC）进行的一项I期试验证明了顺铂加伊立替康的安全性和耐受性。同样在MSKCC进行的一项针对先前未治疗的晚期食管癌患者的该联合方案II期研究也取得了有前景的结果。MSKCC目前的试验正试图将该方案与紫杉醇（泰素）、氟尿嘧啶（5-FU）或放射治疗联合使用。
